



UPLIFT®

New insights into the long-term management of COPD in primary care

**Tuesday 21<sup>st</sup> April 2009, 12.30pm – 6.45pm**

**The Sage Gateshead, St Mary's Square, Gateshead Quays, Gateshead**

**Organised and funded by Boehringer Ingelheim and Pfizer**

Dear Healthcare Professional

**The COPD landscape is changing.** Following the recent publication of the UPLIFT®<sup>1</sup> (Understanding the Potential Long-term Impacts on Function with Tiotropium) study results, I would like to invite you to attend a meeting to discuss new insights into the management of chronic obstructive pulmonary disease (COPD). This meeting has been organised and funded by Boehringer Ingelheim and Pfizer.

This meeting will provide an overview of the rationale, methodology and results from this landmark, four-year, global trial and, importantly, explore the implications for COPD management within primary care. The meeting also includes an update on healthcare policy and care provision relating to COPD management, as well as three interactive workshop sessions.

The meeting will provide an opportunity for primary care professionals to engage in interactive discussion with national COPD leaders and local experts about the issues affecting your patients. A certificate of attendance will be awarded to delegates in recognition of their participation.

To secure your place at the meeting please return either the enclosed fax back registration form or contact your local Boehringer Ingelheim or Pfizer representative.

Please find a meeting overview below.

### **Meeting overview**

**12.30pm Registration and hot buffet lunch**

**1.15pm Welcome and introduction**

**Dr Mike Scott, Chair**  
*GP, Newburn Surgery,  
Joint Chair Newcastle West PBC  
Group*

**1.30pm COPD - the missing millions**

**Bev Wears**  
*Support and Development  
Manager, British Lung  
Foundation, North of England*



<b>2.00pm</b>	<b>UPLIFT® - the outcomes</b>	<b>Dr Lorcan McGarvey</b> <i>Consultant Physician, Royal Victoria Hospital, Belfast</i>
<b>2.45pm</b>	<b>Local COPD guidelines</b>	<b>Dr Mike Scott</b>
<b>3.15pm</b>	<b>Break and refreshments</b>	
<b>3.30pm</b>	<b>Workshops (delegates will be split into 3 groups and rotate)</b>	
	<b>1) COPD and cognitive behavioural therapy</b>	<b>Karen Heslop</b> <i>Respiratory Nurse Specialist, Royal Victoria Infirmary, Newcastle</i>
	<b>2) Quality of spirometry in COPD management</b>	<b>Bev Dredge</b> <i>Clinical Leader for Specialist Services Middlesbrough, Redcar and Cleveland Community Services</i>
	<b>3) COPD: PBC perspective and the respiratory framework</b>	<b>David Thorne</b> <i>Managing Director, Blue River Consulting Ltd, Newcastle</i>
<b>5.45pm</b>	<b>Light finger buffet and refreshments</b>	
<b>6.00pm</b>	<b>COPD management - the way forward</b>	<b>Dr Graham Burns</b> <i>Respiratory Consultant, Royal Victoria Infirmary, Newcastle</i>
<b>6.30pm</b>	<b>Closing remarks</b>	<b>Dr Mike Scott</b>
<b>6.45pm</b>	<b>Depart</b>	

**To secure your place at the meeting please either return the enclosed fax back registration form or contact your local Boehringer Ingelheim or Pfizer representative.**

We look forward to welcoming you on Tuesday 21<sup>st</sup> April.

Yours faithfully,

**Mayang Patel, Territory Sales Manager, Boehringer Ingelheim**

Email: [mayang.patel@boehringer-ingelheim.com](mailto:mayang.patel@boehringer-ingelheim.com)

Mobile: 07778 581953

**Karen Wilson, Sales Representative, Pfizer**

Email: [karen.ukff.wilson@pfizer.com](mailto:karen.ukff.wilson@pfizer.com)

Mobile: 07973 235646

References: 1) Tashkin DP, Celli B, Senn S et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med 2008; 359(15):1543-1554



**If you would like further information on SPIRIVA or SPIRIVA RESPIMAT, please contact Medical Information on 0845 602 3809**

Prescribing Information (UK)

SPIRIVA® RESPIMAT® ▼, SPIRIVA® (tiotropium) Long acting, specific antimuscarinic agent, available as: Spiriva Respimat -solution for inhalation containing tiotropium bromide monohydrate equivalent to 2.5 microgram tiotropium for inhalation with the Respimat device, or, Spiriva -hard capsules of powder for inhalation containing tiotropium bromide monohydrate equivalent to 18 microgram tiotropium for inhalation with the HandiHaler® device. **Indication** Tiotropium is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD). **Dose** Adults only age 18 years or over: For Spiriva Respimat, 5 microgram tiotropium given as two puffs once daily, at the same time of the day. For Spiriva, inhalation of the contents of one capsule once daily from the HandiHaler. **Contra-indications** Hypersensitivity to tiotropium bromide, atropine or its derivatives, e.g. ipratropium or oxitropium or to any of the excipients: lactose monohydrate which contains milk protein (capsules only); benzalkonium chloride, disodium edetate, purified water, hydrochloric acid 3.6 % (for pH adjustment)(solution only). **Precautions** Not for the initial treatment of acute episodes of bronchospasm, i.e. rescue therapy. Immediate hypersensitivity reactions may occur after administration. Caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction. Inhaled medicines may cause inhalation-induced bronchospasm. In patients with moderate to severe renal impairment tiotropium bromide should be used only if the expected benefit outweighs the potential risk. Patients should be cautioned to avoid getting the powder or spray into their eyes. They should be advised that this may result in precipitation or worsening of narrow-angle glaucoma, eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema. Should any combination of these eye symptoms develop, patients should stop using tiotropium bromide and consult a specialist immediately. Tiotropium bromide should not be used more frequently than once a day. Spiriva capsules contain 5.5mg lactose monohydrate. **Interactions** Although no formal drug interaction studies have been performed, tiotropium bromide has been used concomitantly with other drugs commonly used in the treatment of COPD, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids without clinical evidence of drug interactions. The co-administration of tiotropium bromide with other anticholinergic-containing drugs has not been studied and is therefore not recommended. **Pregnancy and Lactation** No documented clinical data on exposed pregnancies are available. The potential risk for humans is unknown. Tiotropium bromide should therefore only be used during pregnancy when clearly indicated. It is unknown whether tiotropium bromide is excreted in human breast milk. Use of tiotropium bromide during breast feeding is not recommended. A decision on whether to continue/discontinue breast feeding or therapy with tiotropium bromide should be made taking into account the benefit of breast feeding to the child and the benefit of tiotropium bromide therapy to the woman. **Effects on ability to drive and use machines** No studies have been performed. The occurrence of dizziness, blurred vision or headache may influence the ability to drive and use machinery. **Side-effects** In clinical trials, dry mouth was the most commonly reported adverse event. Dry mouth occurred in approximately 3% of patients for Spiriva (5437 patients from 19 pooled placebo-controlled clinical trials) and 6% of patients for Spiriva Respimat (849 patients pooled from four placebo controlled clinical trials). Dry mouth was usually mild and often resolved with continued treatment. Serious undesirable effects consistent with anticholinergic effects include constipation, intestinal obstruction including ileus paralytic, and urinary retention, although none was attributed to tiotropium by clinical trial investigators for Spiriva and none were reported in the tiotropium Respimat development programme. Urinary retention was usually observed in elderly men with predisposing factors, (e.g. prostatic hyperplasia). Uncommon undesirable effects reported for Spiriva Respimat were: dizziness, headache, blurred vision, palpitations, supraventricular tachycardia, atrial fibrillation, cough, pharyngitis and other application site irritation, dysphonia, oral candidiasis, gastrooesophageal reflux disease, dysphagia, pruritus, dysuria and urinary retention. Uncommon undesirable effects reported for Spiriva were: oral candidiasis, nausea, dizziness, headache, taste disorders, bronchospasm, cough, pharyngitis and dysphonia. In addition, local upper airway irritant phenomena have been observed in patients receiving tiotropium bromide. In common with all inhaled medicines, tiotropium may cause inhalation-induced bronchospasm. An increased incidence of dry mouth and constipation may occur with increasing age. Prescribers should consult the individual product SPC in relation to other undesirable effects. **Pack size and basic NHS prices** Combopack HandiHaler device and 30 capsules (3 blister strips) £36.27 Refill Pack 30 capsules (3 blister strips) £33.17 PL 14598/0062. Single pack: 1 Respimat inhaler and 1 cartridge, providing 60 puffs (30 medicinal doses) £36.27 PL 14598/0084. **Legal category POM Product Licence holder** Boehringer Ingelheim International GmbH, D-55216 Ingelheim am Rhein, Germany. For full prescribing information please see individual product SPC. Updated February 2009.

Spiriva has been developed by Boehringer Ingelheim and is being co-promoted by Pfizer Limited and Boehringer Ingelheim Limited.

**Adverse events should be reported. Reporting forms and information can be found at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk) . Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).**





UPLIFT®

New insights into the long-term management of COPD in primary care

**Fax Back Registration Form**  
**Fax back to: 020 7853 2244 by Friday 17<sup>th</sup> April**

Tuesday 21<sup>st</sup> April, 2009, 12.30pm – 6.45pm  
The Sage Gateshead, St Mary’s Square, Gateshead Quays, Gateshead

Please tick the appropriate box

- I would like to attend the UPLIFT® meeting.
- Unfortunately I am unable to attend the UPLIFT® meeting, but would like to receive further information about the UPLIFT® trial.

Your full postal address or email is needed in order to confirm your place at the meeting.

Name.....

Practice.....

Address.....

E-mail.....

Tel number.....

It is agreed that by completing the above, you give consent to Pfizer and Boehringer Ingelheim (and any agents acting on their behalf) for the processing of your personal information for the purposes set out above. Your information will be held on a database within the European Economic Area (EEA). Your information may be transferred within or outside of the EEA (including to the USA) where privacy laws may be less strict than in the UK, but we will always employ appropriate technical security measures to protect your personal information and to ensure that it is not accessed by unauthorised persons. You will at any time have the right to access your information, or to request that your information on the database is amended or deleted, or to request further details on our privacy policy in writing. To do so, please contact Alison Wheeler by post at Pfizer Ltd. Walton Oaks (IPC 3-G-25), Dorking Road, Walton-On-The-Hill, Surrey, KT20 7NS, by email at [alison.wheeler@pfizer.com](mailto:alison.wheeler@pfizer.com), or by phone on 01737 330635. Alternatively, please contact Natalie Wilson by post at Boehringer Ingelheim, Ellesfield Avenue, Bracknell, Berks, RG12 8YS, by email at [natalie.wilson@boehringer-ingelheim.com](mailto:natalie.wilson@boehringer-ingelheim.com), or by phone on 01344 741247.

Organised and funded by Boehringer Ingelheim and Pfizer

